This strategy includes the induction of immunogenic cell death (ICD) to release adenosine triphosphate (ATP), calreticulin (CRT), and high mobility group box protein 1 (HMGB-1) for the recruitment of dendritic cells (DCs) that phagocytize cancer cells or their antigens [4,6,7,8,9], suppression of immunosuppressive pathways of cancer cells [10] or cancer-associated ECM-resident cells [11], or inhibition of the signals associated with the immune checkpoints between cancer cells and immune cells [3,7,12,13,14]. Here, HMGB1 is linked to cancer.